VZV-associated acute retinal necrosis in a patient with MS treated with natalizumab

@inproceedings{Pawlitzki2018VZVassociatedAR,
  title={VZV-associated acute retinal necrosis in a patient with MS treated with natalizumab},
  author={Marc Pawlitzki and Jan Teuber and Christin Campe and Markus Wagner and Claudia Schuart and Friedemann Paul and Dominik Bittner},
  booktitle={Neurology(R) neuroimmunology & neuroinflammation},
  year={2018}
}
Natalizumab (NTZ) was the first approved humanized monoclonal antibody in highly active relapsing remitting MS (RRMS). Because of the mechanism of inhibiting the migration of immune cells through the blood-brain barrier into the CNS, NTZ is associated with an increased risk of progressive multifocal leukoencephalopathy (PML) by the John Cunningham virus… CONTINUE READING